KRW 8370.0
(-1.53%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 6.94 Billion KRW | -58.48% |
2022 | 16.71 Billion KRW | -9.17% |
2021 | 18.4 Billion KRW | 350.64% |
2020 | 4.08 Billion KRW | 29.84% |
2019 | 3.14 Billion KRW | -4.96% |
2018 | 3.3 Billion KRW | -31.91% |
2017 | 4.86 Billion KRW | -5.93% |
2016 | 5.16 Billion KRW | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 6.96 Billion KRW | 0.37% |
2024 Q2 | 10.47 Billion KRW | 50.32% |
2023 Q4 | 6.94 Billion KRW | -13.46% |
2023 FY | 6.94 Billion KRW | -58.48% |
2023 Q3 | 8.02 Billion KRW | -6.6% |
2023 Q2 | 8.58 Billion KRW | -18.03% |
2023 Q1 | 10.47 Billion KRW | -37.33% |
2022 Q2 | 19.07 Billion KRW | 6.8% |
2022 Q1 | 17.86 Billion KRW | -2.93% |
2022 Q3 | 19.42 Billion KRW | 1.81% |
2022 Q4 | 16.71 Billion KRW | -13.94% |
2021 Q4 | 18.4 Billion KRW | 2.28% |
2021 Q3 | 17.99 Billion KRW | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 27.25 Billion KRW | 74.534% |
InBody Co.,Ltd | 24.62 Billion KRW | 71.809% |
Seegene, Inc. | 221.05 Billion KRW | 96.86% |
i-SENS, Inc. | 195.32 Billion KRW | 96.446% |
Ray Co., Ltd. | 128.35 Billion KRW | 94.592% |
Gencurix Inc. | 21.49 Billion KRW | 67.714% |
Sugentech Inc. | 20.73 Billion KRW | 66.52% |
L&C Bio Co., Ltd | 105.37 Billion KRW | 93.413% |